Ss Pierangeli

Summary

Affiliation: University of Texas Medical Branch
Country: USA

Publications

  1. doi request reprint Acquired and inherited thrombophilia disorders in pregnancy
    Silvia S Pierangeli
    Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch Galveston, TX 77555 0883, USA
    Obstet Gynecol Clin North Am 38:271-95, x. 2011
  2. ncbi request reprint New targeted therapies for treatment of thrombosis in antiphospholipid syndrome
    Silvia S Pierangeli
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 1165, USA
    Expert Rev Mol Med 9:1-15. 2007
  3. doi request reprint A protocol for determination of anticardiolipin antibodies by ELISA
    Silvia S Pierangeli
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    Nat Protoc 3:840-8. 2008
  4. doi request reprint Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms
    Silvia S Pierangeli
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 1165, USA
    Semin Thromb Hemost 34:236-50. 2008
  5. doi request reprint A quarter of a century in anticardiolipin antibody testing and attempted standardization has led us to here, which is?
    Silvia S Pierangeli
    Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 1165, USA
    Semin Thromb Hemost 34:313-28. 2008
  6. pmc Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies
    Silvia S Pierangeli
    Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555 1165, USA
    Ann Rheum Dis 66:1327-33. 2007
  7. doi request reprint Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?
    S S Pierangeli
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 0883, USA
    Lupus 19:475-85. 2010
  8. ncbi request reprint Novel therapies for the antiphospholipid syndrome
    Silvia S Pierangeli
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA
    Expert Rev Clin Immunol 4:193-203. 2008
  9. doi request reprint 'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010
    S S Pierangeli
    Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 0883, USA
    Lupus 20:182-90. 2011
  10. ncbi request reprint C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies
    Zurina Romay-Penabad
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555 1165, USA
    Ann N Y Acad Sci 1108:554-66. 2007

Research Grants

Collaborators

Detail Information

Publications30

  1. doi request reprint Acquired and inherited thrombophilia disorders in pregnancy
    Silvia S Pierangeli
    Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch Galveston, TX 77555 0883, USA
    Obstet Gynecol Clin North Am 38:271-95, x. 2011
    ..This article reviews the most up-to-date knowledge of prevalence, pathogenesis, and diagnosis of acquired and inherited thrombophilias and their relationship and association with pregnancy complications...
  2. ncbi request reprint New targeted therapies for treatment of thrombosis in antiphospholipid syndrome
    Silvia S Pierangeli
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 1165, USA
    Expert Rev Mol Med 9:1-15. 2007
    ..Based on this information and on additional scientific evidence using in vitro and in vivo models, new potential targeted therapies for treatment and/or prevention of thrombosis in APS are proposed and discussed...
  3. doi request reprint A protocol for determination of anticardiolipin antibodies by ELISA
    Silvia S Pierangeli
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    Nat Protoc 3:840-8. 2008
    ..This article details a procedure that takes approximately 2 h and summarizes the information available on the aCL ELISA test...
  4. doi request reprint Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms
    Silvia S Pierangeli
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 1165, USA
    Semin Thromb Hemost 34:236-50. 2008
    ..Based on experimental evidence using in vitro and in vivo models, new targeted therapies for treatment and/or prevention of thrombosis and pregnancy loss in antiphospholipid syndrome are proposed...
  5. doi request reprint A quarter of a century in anticardiolipin antibody testing and attempted standardization has led us to here, which is?
    Silvia S Pierangeli
    Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 1165, USA
    Semin Thromb Hemost 34:313-28. 2008
    ....
  6. pmc Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies
    Silvia S Pierangeli
    Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555 1165, USA
    Ann Rheum Dis 66:1327-33. 2007
    ....
  7. doi request reprint Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?
    S S Pierangeli
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 0883, USA
    Lupus 19:475-85. 2010
    ....
  8. ncbi request reprint Novel therapies for the antiphospholipid syndrome
    Silvia S Pierangeli
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA
    Expert Rev Clin Immunol 4:193-203. 2008
    ..Based on experimental evidence using in vitro and in vivo models, new targeted therapies for treatment and/or prevention of thrombosis in APS are proposed and discussed...
  9. doi request reprint 'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010
    S S Pierangeli
    Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 0883, USA
    Lupus 20:182-90. 2011
    ..This report summarizes the findings, conclusions, and recommendations of this Task Force...
  10. ncbi request reprint C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies
    Zurina Romay-Penabad
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555 1165, USA
    Ann N Y Acad Sci 1108:554-66. 2007
    ..The data indicate that C5aR-/- mice are protected from the thrombogenic effects of some aPL antibodies...
  11. doi request reprint Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo
    Zurina Romay-Penabad
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 1165, USA
    Blood 114:3074-83. 2009
    ..Together, these data indicate for the first time that A2 mediates the pathogenic effects of aPL antibodies in vivo and in vitro APS...
  12. doi request reprint Statins for the treatment of antiphospholipid syndrome?
    Praveen Jajoria
    Department of Internal Medicine, Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, Texas 77555 0883, USA
    Ann N Y Acad Sci 1173:736-45. 2009
    ..The data from this study show that statins may be beneficial in aPL-positive patients and warrant larger clinical trials to confirm the efficacy of the drug for the treatment of APS clinical manifestations...
  13. pmc Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity
    Gangduo Wang
    University of Texas Medical Branch, Galveston, TX 77555 0438, USA
    Arthritis Rheum 62:2064-72. 2010
    ..This study was undertaken to investigate the status and contribution of oxidative/nitrosative stress in patients with SLE...
  14. ncbi request reprint B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients
    William Stohl
    Division of Rheumatology, Department of Medicine, Los Angeles County, Los Angeles, CA, USA
    Clin Immunol 104:115-22. 2002
    ..This raises the possibility that the combination of a BLyS protein antagonist with an agent that targets (helper) T cells may have salutary synergistic effects on autoantibody production in diseases such as systemic lupus erythematosus...
  15. ncbi request reprint Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets
    Mariano E Vega-Ostertag
    Laboratory of Hemostasia and Thrombosis, Instituto Fares Taie, Rivadavia, Mar del Plata, Buenos Aires, Argentina
    Curr Rheumatol Rep 9:190-7. 2007
    ..This review discusses and summarizes the most current data available on molecular interactions and pathogenic mechanisms in antiphospholipid syndrome...
  16. ncbi request reprint Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms
    Silvia S Pierangeli
    Department of Microbiology, Biochemistry and Immunology Morehouse School of Medicine, Atlanta, GA 30310 1459, USA
    Curr Opin Hematol 13:366-75. 2006
    ..Since its recognition in the 1980s, growing interest in the field, not only with respect to diagnosis and treatment, but also regarding the pathogenesis of antiphospholipid antibodies, has emerged...
  17. ncbi request reprint Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome
    Silvia S Pierangeli
    Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310 1495, USA
    Ann N Y Acad Sci 1051:413-20. 2005
    ..Our data show that complement activation mediates two important effectors of aPL antibodies: induction of thrombosis and endothelial activation...
  18. ncbi request reprint Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo
    Azzudin E Gharavi
    Department of Medicine, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310 1495, USA
    Arthritis Rheum 46:545-52. 2002
    ..To characterize the binding and functional properties of antiphospholipid antibodies (aPL) induced by immunization with a viral peptide and to determine whether aPL are pathogenic in vivo...
  19. ncbi request reprint Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies
    Ricardo G Espinola
    Department of Microbiology, Morehouse School of Medicine, Atlanta, Georgia 30310 1495, USA
    Thromb Haemost 87:518-22. 2002
    ..0125 mM). This suggests at least one possible mechanism by which HQ may prevent thrombosis. This may have important implications in treatment of thrombosis in APS patients...
  20. ncbi request reprint Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model
    Dardo E Ferrara
    Morehouse School of Medicine, Atlanta, Georgia 30310 1495, USA
    Arthritis Rheum 48:3272-9. 2003
    ..This study uses an in vivo mouse model to investigate whether fluvastatin has an effect on decreasing both the adhesion of leukocytes to ECs and the thrombus formation induced by aPL...
  21. ncbi request reprint Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin
    Mariano Vega-Ostertag
    Morehouse School of Medicine, Atlanta, Georgia 30310, USA
    Arthritis Rheum 50:2911-9. 2004
    ..The intracellular events involved in aPL-mediated platelet activation are not fully understood and are therefore the subject of this study...
  22. ncbi request reprint Primary, Secondary, Catastrophic Antiphospholipid Syndrome: is there a difference?
    E Nigel Harris
    Morehouse School of Medicine, 720 Westview Dr SW, Atlanta, GA 30310 1495, USA
    Thromb Res 114:357-61. 2004
    ....
  23. ncbi request reprint Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies
    Silvia S Pierangeli
    Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310 1495, USA
    Thromb Res 114:467-76. 2004
    ....
  24. ncbi request reprint Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies
    Mariano Vega-Ostertag
    Morehouse School of Medicine, Atlanta, Georgia, USA
    Arthritis Rheum 52:1545-54. 2005
    ....
  25. ncbi request reprint Clinical laboratory testing for the antiphospholipid syndrome
    Silvia S Pierangeli
    Department of Microbiology, Biochemistry and Immunology, USA
    Clin Chim Acta 357:17-33. 2005
    ..Therefore, it is now recommended to include both tests, IgA aCL and IgG, IgM and IgA anti-beta2GPI to confirm diagnosis of APS...
  26. ncbi request reprint Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia
    Silvia S Pierangeli
    Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, Georgia 30310 1495, USA
    Arthritis Rheum 52:2120-4. 2005
    ..In this study, we tested the hypothesis that aPL are responsible for activation of complement, thus generating split products that induce thrombosis...
  27. pmc Complement C3 activation is required for antiphospholipid antibody-induced fetal loss
    V Michael Holers
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Exp Med 195:211-20. 2002
    ..While antigenic epitopes recognized by aPL antibodies are important in the pathogenesis of APS, our data show that in vivo complement activation is required for aPL antibody-induced fetal loss and growth retardation...
  28. ncbi request reprint Diverse effects of statins on endothelial cells?
    Dardo E Ferrara
    Thromb Haemost 93:186-8. 2005
  29. ncbi request reprint A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo
    Silvia S Pierangeli
    Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr SW, Rm 331 BSMB, Atlanta, GA 30310 1495, USA
    J Autoimmun 22:217-25. 2004
    ..Peptide A is also found in region I/II of beta2GPI. A scrambled form of peptide A (named scA, GTKGCPNVRLT) was used as a control...
  30. ncbi request reprint Viral origin of antiphospholipid antibodies: endothelial cell activation and thrombus enhancement by CMV peptide-induced APL antibodies
    Azzudin E Gharavi
    Dept of Medicine, Morehouse School of Medicine, University of Atlanta, Atlanta Georgia 30310 1495, USA
    Immunobiology 207:37-42. 2003
    ..Alternatively, free peptides may be used to induce tolerance against aPL production...

Research Grants1

  1. Antiphospholipid antibodies and lupus: new molecular targets for treatment
    Silvia S Pierangeli; Fiscal Year: 2010
    ..These studies may help to devise new more specific and less harmful modalities than the anticoagulation or general immunosuppression currently used to treat and prevent thrombosis in patients with aPL Abs. ..